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"Diagnostic Method and Kit"
Field of the Invention
The invention relates to methods and kits for the
diagnosis and/or herd profiling of Mycobacterium
infected or contaminated animals.
Background to the Invention
Tuberculosis (TB) , one of the most widespread
infectious diseases, is the leading cause of death
due to a single infectious agent among adults in the
world. Mycobacterium tuberculosis is the most common
cause of human TB.
In order to monitor and control the disease, herd
profiling is necessary. However, the methods
currently used to monitor tuberculosis in animals
suffer from a number of drawbacks. Nowadays, the
disease control programmes for bovine TB carried out
in most countries are based on a test and removal
strategy utilizing the intradermal skin test, which
relies on PPD, a purified protein derivative of M .
bovis strain AN5, to elicit an immune response in
infected cattle.
In cattle, the intradermal skin tests currently used
are the Caudal-fold Tuberculin Test (CFT) and the
Comparative cervical tuberculin test (CCT) . The
Caudal-fold Tuberculin Test (CFT) is the primary
screening test used to identify cattle herds
potentially infected with bovine tuberculosis. It
measures the immune response to Purified Protein
Derivative (PPD) tuberculin (M. bovis AN5) . However,
in 5% of cases, the CFT test may result in false-
positive test results or, in 15% of cases, in false-
negative test results. Disease control based on the
skin test can be complemented by the gamma-
interferon test, which measures an animal's T cell
response when exposed to PPD material. The gamma-
interferon test is utilised as a second line
diagnostic for skin test positive' animals.
One of the problems associated with the complex
antigenic nature of mycobacteria is the definition
of those proteins which are important targets of the
immune system and are thus likely present in large
numbers of field samples. It is also important to
recognize that there is regional variation in the
infectious mycobacterial strains, for example M .
bovis strains.
An antibody assay developed using strain specific
proteins could resolve both specificity and
sensitivity issues.
A number of methods of discriminating between
strains of tuberculosis have been suggested. US
6,686,166B, WO 2004/083448A, US2004/00 63923A, and US
6,291,19OB describe 129 genetic marker sequences
which are suggested for use in the identification of
strains of mycobacteria. However, many markers are
not expressed sufficiently to reliably be used in
the identification of a strain. Further, as
described further below, the amount of expression of
individual markers varies considerably, not only
between strains, but within strains geographically
and within strains dependent on the stage of
infection .
US2005/0272104A suggests the use of the PPD antigens
ESAT-6 and CFP-IO in the detection of Mycobacterium
tuberculosis in humans. In general however, antibody
(Ab) tests based upon PPD tuberculins are
characterised by a low discriminating power, with
the distribution of the antibody titers between
infected and non-infected animals being widely
overlapping (Amadori et al . 1998).
US 7,192,721 describes a test kit for detection of
TB in different non-primate mammals, the kit
comprising a mycobacterial antigen cocktail
comprising ESAT-6/CFP10 and 16kDa/MPB83 fusion
proteins. In a sample of 85 cattle, the sensitivity
demonstrated was 79%; however, in 513 cattle, the
sensitivity was 73%.
Due to the heterogeneity of the disease, no single
antigen is present in all cases of infection.
However, although a great many antigens associated
with tuberculosis infection have been identified in
the prior art, the need remains for particular
combinations which may be used in a test with
improved levels of sensitivity and specificity to
avoid the many false positive and false negative
test results associated with conventional TB
testing.
Although many antigens have been identified, by
simply increasing the number of antigens in a test
kit, the sensitivity and specificity of the test may
not necessarily be improved. It is recognised in
the art that, where diagnostic kits comprise too
many antigenic additional antigens, the specificity
and sensitivity of the kit may in fact be reduced.
For example, US 792,721 describes a decrease in
sensitivity and specificity associated with
increasing the number of antigens used in the kits
described therein. Thus, crucial to the design of
an effective kit is the selection of antigens to be
used therein.
As well as the problems discussed above with respect
to identification of antigens for reliable diagnosis
of tuberculosis infection, the formats of many
diagnostic kits currently used may contribute to the
lack of reliability. Cumulative results from animals
experimentally infected with Mbv (M. bovis) have
shown there may be a transient antibody response to
some antigens that occur at different stages of
infection, further complicating development of a
diagnostic assay (Amadori,et al 2002. Vet.
Microbiol. 85:379-389). The advances that have been
made show that some of the difficulties in
developing an optimal assay can be overcome by
including multiple antigens in the assay (Aagaard,
et al 2006. J . Clin. Microbiol. 44:4326-4335.,
Amadori,et al 2002. Vet. Microbiol. 85:379-389).
Although some success has also been made in
identifying antigens potentially useful in
multiplexed diagnostic assays (Aagaard, et al 2006.
J . Clin. Microbiol. 44:4326-4335., Koo et al 2005.
J . Clin. Microbiol. 43:4498-4506, Lightbody, et al
2000. Vet. Microbiol. 75:177-188, McNair et al
2001. Scand. J . Immunol. 53:365-371., Pollock, J . M .
and P . Andersen. 1997. Infect. Immun. 65:2587-2592,
Pollock, J . M . and P . Andersen. 1997. J . Infect.
Dis. 175:1251-1254, Pollock, et al 2000. Vet. Rec.
146:659-665, Wiker et al 1998. Infect. Immun.
66:1445-1452), the necessity of using multiple
antigens in an assay, has, however, introduced
another challenge. Evaluation of the standard type
of ELISA has shown sensitivity and specificity are
reduced when multiple antigens are combined for
analysis in a single well thus limiting the way a
conventional ELISA can be used (Lyashchenko, et al
2000. J . Immunol. Methods 242:91-100). Fluorescence
polarization has been evaluated as an alternative
platform (Lin et all996. Clin. Diag. Lab. Immunol.
3:438-443, Surujballiet al 2002. Vet. Microbiol.
87:149-157). It has been successfully used in
testing for Mbv in cattle, elk, llamas, and bison
with a single antigen. A further improvement over
an ELISA-based system has been the use of lateral
flow technology (Koo et al 2005. J . Clin. Microbiol.
43:4498-4506, Lyashchenko et al 2000. J . Immunol.
Methods 242:91-100). This methodology has been used
successfully for multiplexing antigens for visual
analysis of patterns of antibody activity at the
single animal level (Greenwald, et al 2003. Diagn.
Microbiol. Infect. Dis. 46:197-203, Lyashchenko, et
al 2006. Clin. Vaccine Immunol. 13:722-732, Waters,
et al 2006. Clin. Vaccine Immunol. 13:648-654,
Waters, et al 2006. Clin. Vaccine Immunol. 13:611-
619, Wernery et al 2007. Vet. Microbiol. 122:108-
115.) . Other areas that have not been fully
explored are electrochemiluminescence (Lu, Y . et al
2006. J . Immunol. Methods 314:74-79, Yan, et al .
2004. J . Immunol. Methods 288:47-54) and
chemiluminescence (Liew et al 2007. Biotechniques
42:327-333). Commercial imaging systems using these
technologies have been developed for multiplexing
and analysis of antibody activity to multiple
antigens (Liew et al 2007. Biotechniques 42:327-333,
Lu, Y . et al 2006. J . Immunol. Methods 314:74-79,
Yan, et al . 2004. J . Immunol. Methods 288:47-54).
The platforms are designed for rapid processing and
analysis of large numbers of samples. However, a
number of problems persist with many of these
methods .
There thus remains the need for an improved test
which can accurately and reliably diagnose the
presence of tuberculosis infection with satisfactory
sensitivity and specificity across different
populations of animals.
PCT/GB2008/050721, which shares the same applicants
as the present application) describes particular
combinations of mycobacterial antigens which may be
used in the diagnosis of TB with high levels of
reliability.
Summary of the Invention
As described herein, the present inventors have
identified a number of polypeptides, which together
are useful for the sensitive specific diagnosis and
profiling of Mycobacterium in a number of different
families of mammals.
Each of the specific polypeptides is capable of
eliciting a strong immune response in the absence of
adjuvant. The characterized proteins/fragments which
are immunogenic (or early antigens) and specific to
one or other mycobacterial strains can be used
reliably for the diagnosis of tuberculosis
infection. As described in the examples, such
polypeptides elicit a strong immune response in
serum from animals immunised with Mycobacterium
bovis. Significantly, the inventors have found that,
when particular combinations of these polypeptides
are used together in an assay, the sensitivity of
tuberculosis testing can be vastly improved over the
sensitivity obtained using prior art methods.
The polypeptides which may be used in the invention
are SEQ ID NOs: 1-13 and variants and fragments
thereof.
In one embodiment of the invention, the polypeptides
which may be used in the invention comprise peptides
having amino acid sequences comprising the amino
acid sequences shown as one or more of SEQ ID NOs:
1-13.
SEQ ID NO: 1 corresponds to Rv3616C (full length)
MSRAFIIDPT ISAIDGLYDL LGIGIPNQGG ILYSSLEYFE
KALEELAAAF PGDGWLGSAA DKYAGKNRNH VNFFQELADL
DRQLISLIHD QANAVQTTRD ILEGAKKGLE FVRPVAVDLT
YIPVVGHALS AAFQAPFCAG AMAVVGGALA YLVVKTLINA
TQLLKLLAKL AELVAAAIAD IISDVADI IK GTLGEVWEFI
TNALNGLKEL WDKLTGWVTG LFSRGWSNLE SFFAGVPGLT
GATSGLSQVT GLFGAAGLSA SSGLAHADSL ASSASLPALA
GIGGGSGFGG LPSLAQVHAA STRQALRPRA DGPVGAAAEQ
VGGQSQLVSA QGSQGMGGPV GMGGMHPSSG ASKGTTTKKY
SEGAAAGTED AERAPVEADA GGGQKVLVRN VV
SEQ ID NO: 2 corresponds to residues 300-370 of
Rv3616c (Mtb40) :
ASTRQALRPRADGPVGAAAEQVGGQSQLVSAQGSQGMGGPVGMGGMHPSSGA
SKGTTTKKYSEGAAAGTED
SEQ ID NO: 3 corresponds to residues 35-94 of
Rv3616c:
SLEYFEKALEELAAAFPGDGWLGSAADKYAGKNRNHVNFFQELADLDRQLIS
LIHDQANA
SEQ ID NO: 4 corresponds to residues 1-34 of
Rv3616c:
MSRAFIIDPTISAIDGLYDLLGIGIPNQGGILYS
SEQ ID NO: 5 corresponds to residues 95-392 of
Rv3616c:
VQTTRDILEGAKKGLEFVRPVAVDLTYIPVVGHALSAAFQAPFCAGAMAVVG
GALAYLVVKTLINATQLLKLLAKLAELVAAAIADIISDVADIIKGTLGEVWE
FITNALNGLKELWDKLTGWVTGLFSRGWSNLESFFAGVPGLTGATSGLSQVT
GLFGAAGLSASSGLAHADSLASSASLPALAGIGGGSGFGGLPSLAQVHAAST
RQALRPRADGPVGAAAEQVGGQSQLVSAQGSQGMGGPVGMGGMHPSSGASKG
TTTKKYSEGAAAGTEDAERAPVEADAGGGQKVLVRNVV
SEQ ID NO: 6 corresponds to MPB70
MKVKNTIAATSFAAAGLAALAVAVSPPAAAGDLVGPGCAEYAAANPTGPASV
QGMSQDPVAVAASNNPELTTLTAALSGQLNPQVNLVDTLNSGQYTVFAPTNA
AFSKLPASTIDELKTNSSLLTSILTYHVVAGQTSPANVVGTRQTLQGASVTV
TGQGNSLKVGNADVVCGGVSTANATVYMIDSVLMPPA
SEQ ID NO: 7 corresponds to PEP1(MPB7O):
KGSGS SVQGMSQDPVAVAASNNPEL
SEQ ID NO: 8 corresponds to MPB83
MINVQAKPAAAASLAAIAIAFLAGCSSTKPVSQDTSPKPATSPAAPVTTAAM
ADPAADLIGRGCAQYAAQNPTGPGSVAGMAQDPVATAASNNPMLSTLTSALS
GKLNPDVNLVDTLNGGEYTVFAPTNAAFDKLPAATIDQLKTDAKLLSSILTY
HVIAGQASPSRIDGTHQTLQGADLTVIGARDDLMVNNAGLVCGGVHTANATV
YMIDTVLMPPAQ
SEQ ID NO: 9 corresponds to Rv3875 (ESAT6) :
TEQQWNFAGIEAAASAIQGNVTSIHSLLDEGKQSLTKLAAAWGGSGSEAYQG
VQQKWDATATELNNALQNLARTISEAGQAMASTEGNVTGMFA
SEQ ID NO: 10 corresponds to Rv3874 (CFPlO) :
AEMKTDAATLAQEAGNFERISGDLKTQIDQVESTAGSLQGQWRGAAGTAAQA
AVVRFQEAANKQKQELDEISTNIRQAGVQYSRADEEQQQALSSQMGF
SEQ ID NO: 11 corresponds to PEP4 (CFPlO)
KGSGS MAEMKTDAATLAQEAGN
SEQ ID NO: 12 corresponds to PEP9 (CFPlO)
KGSGS NIRQAGVQYSRADEEQQQ
SEQ ID NO: 13 corresponds to PEP 17 (CFPlO)
VVRFQEAANKQKQELDE I
Other polypeptides which may be used in the
invention comprise peptides having amino acid
sequences comprising the amino acid sequences shown
as one or more of SEQ ID NOs: 14-16.
SEQ ID NO: 14 corresponds to Rvl573:
MTTTPARFNHLVTVTDLETGDRAVCDRDQVAETIRAWFPDAPLEVREALVRL
QAALNRHEHTGELEAFLRISVEHADAAGGDECGPAILAGRSGPEQAAINRQL
GLAGDDEPDGDDTPPWSRMIGLGGGSPAEDER
SEQ ID NO: 15 corresponds to Rvl580c:
MAETPDHAELRRRIADMAFNADVGMATCKRCGDAVPYI ILPNLQTGEPVMGV
ADNKWKRANCPVDVGKPCPFLIAEGVADSTDDTIEVDQ
SEQ ID NO: 16 corresponds to Rvl585c:
MSRHHNIVIVCDHGRKGDGRIEHERCDLVAPI IWVDETQGWLPQAPAVATLL
DDDNQPRAVIGLPPNESRLRPEMRRDGWVRLHWEFACLRYGAAGVRTCEQRP
VRVRNGDLQTLCENVPRLLTGLAGNPDYAPGFAVQS DAVVVAMWLWRTLCE S
DTPNKLRATPTRGSC
Underlined sequences, as shown above for some
peptides, were added to enhance the hydrophilicity
of the peptides for binding to the surface. Where
reference is made herein to use of such peptides, it
should be understood that such peptides may be
employed with or without the hydrophilicity
enhancing sequence.
The inventors have found that the peptides having
amino acid sequences SEQ ID NO: 1 to SEQ ID NO: 13
each elicit a strong immune response in serum from
animals challenged with mycobacterial strains.
Significantly, the inventors have found that by
employing one of two combinations of only five of
these antigens, the presence of tuberculosis may be
identified in animals with a degree of sensitivity
hitherto not obtainable. Furthermore the inventors
have also shown that a diagnostic test for
tuberculosis infection demonstrating both high
sensitivity and specificity may be based on either
of these combinations.
Accordingly, in a first aspect of the invention,
there is provided a method of diagnosis of
tuberculosis in an animal, the method comprising the
steps :
providing a biological sample from said animal; and
determining the presence or absence of a group of
antigens, or the presence or absence of an immune
response to each member of said group of antigens,
wherein said group of antigens comprises the group
consisting of (i)an Rv3616 antigen, (ii) an MPB70
antigen, (iii) an MPB70 linear epitope, for example
PEPl (MPB70) (iv) an MPB83 antigen, and (v) at least
one of (a) a CFPlO antigen and (b) an ESAT 6
antigen; wherein the identification of the presence
of two or more of said antigens of said group of
antigens, or of an immune response thereto, is
indicative of the presence of tuberculosis infection
in the animal.
In a second aspect, the present invention provides
an assay for the detection of the presence of
Mycobacterium, for example Mycobacterium bovis, in a
biological sample, said method comprising the steps:
providing a biological sample from said animal;
and determining the presence or absence of a group
of antigens, or the presence or absence of an immune
response to each member of said group of antigens,
wherein said group of antigens comprises the group
consisting of (i) an Rv3616 antigen, (ii) an MPB70
antigen, (iii) an MPB70 linear epitope, for example
PEPl (MPB70) (iv) an MPB83 antigen, and (v) at least
one of (a) a CFPlO antigen and (b) an ESAT 6
antigen;
wherein the identification of the presence of
two or more of said antigens or of an immune
response thereto is indicative of the presence of
Mycobacterium in the biological sample.
In one embodiment of the first and second aspects of
the invention, the method does not comprise the
determination of the presence or absence of any
mycobacterial antigen, or an immune response
thereto, other than (i) an Rv3616 antigen, (ii) an
MPB70 antigen, (iii) an MPB70 linear epitope, for
example PEPl (MPB70) (iv) an MPB83 antigen, and (v)
at least one of (a) a CFPlO antigen and (b) an ESAT
6 antigen.
In one embodiment of the first or second aspect of
the invention, the group of antigens comprises (a) a
CFPlO antigen but does not comprise (b) an ESAT-6
antigen .
In another embodiment of the first or second aspect
of the invention, the group of antigens comprises an
ESAT-6 antigen but does not comprise a CFPlO
antigen .
Unless the context demands otherwise, where
reference is made to a CFPlO antigen, such reference
should be understood to encompass one or more of a
CFPlO antigen having the sequence shown as SEQ ID
NO: 10, a pep4 (CFPlO) antigen having the sequence
shown as SEQ ID NO: 11, a pep9 (CFPlO) antigen
having the sequence shown as SEQ ID NO: 12, or a
pepl7 (CFPlO) antigen having the sequence shown as
SEQ ID NO: 13.
However, in one particular embodiment, the CFPlO
antigen has the sequence shown as SEQ ID NO: 10.
Likewise where reference is made to a Rv3616c
antigen, such reference should be understood to
encompass one or more of a Rv3616c antigen having
the sequence shown as SEQ ID NO: 1 , SEQ ID NO: 2 ,
SEQ ID NO: 3 , SEQ ID NO: 4 , or SEQ ID NO: 5 .
The present inventors have established that, even if
an animal has been exposed to bovine PPD, the
detectable immune response to the PPD test, in many
cases, decreases rapidly after the initial exposure.
Thus, although exposure to one or more of these
antigens may be detectable in an animal uninfected
with tuberculosis but which has been tested with
bovine PPD within 2 weeks of the PPD test, within
one month or so, the antigenic response will, in
many cases, be undetectable. Thus, in general,
unless a particular herd has been tested with PPD
within one month preceding testing the animals with
the method or kit of the present invention, the
identification of the presence of an immune response
to one or more of these antigens should be
indicative of infection with Mycobacterium bovis and
not merely exposure to bovine PPD.
However, the antigens having SEQ ID NO: 14, SEQ ID
NO: 15 and SEQ ID NO: 16 (rvl573, Rvl580c and
Rvl585c) are not expressed in bovine PPD and thus
may be used to confirm that the presence of a
positive result is indicative of infection with
bovine tuberculosis and not merely of past exposure
to PPD via e.g. the intradermal skin test.
Accordingly, in one embodiment of the first and
second aspects of the invention, the method further
includes determining the presence or absence of at
least one of the antigens, or an immune response to
at least one of the antigens, of the group
consisting of an Rvl573 antigen, an Rvl580c antigen
and an Rvl585c antigen. The identification of the
presence of one or more of the Rvl573 antigen, the
Rvl580c antigen and the Rvl585c antigen or of an
immune response thereto is confirmatory of the
presence of, or infection with, Mycobacterium bovis.
The methods of the invention may be used with any
animal, for example any mammal, including humans, or
bird. In one embodiment, the animal is a mammal.
In one particular embodiment, the mammal is a non-
human mammal .
In a particular embodiment of the invention, the
mammal is a domesticated animal, such as a farm
animal. In a particular embodiment the mammal is of
the family bovidae. The bovidae include cattle,
goats, sheep, antelopes and gazelles. In one
embodiment, the mammal is a cow. In another
embodiment, the mammal is a goat.
In a particular embodiment of the invention, the
mammal is a goat and the group of antigens comprises
(i) an Rv3616 antigen, (ii) an MPB70 antigen, (iii)
an MPB70 linear epitope, for example PEPl (MPB70)
(iv) an MPB83 antigen, and (v) a CFPlO antigen.
In another particular embodiment of the invention,
the mammal is a goat and the group of antigens
consists of (i) an Rv3616 antigen, (ii) an MPB70
antigen, (iii) an MPB70 linear epitope, for example
PEPl (MPB70) (iv) an MPB83 antigen, and (v) a CFPlO
antigen .
In a further embodiment of the invention the mammal
is a cervid.
In a further embodiment of the invention the mammal
is a suidae mammal, for example pig, swine ,hog or
wild boar. In one particular embodiment, the suidae
mammal is a wild boar.
Moreover, as described in the Examples, the
inventors have established that tuberculosis can be
identified with high sensitivity and selectivity in
cervids and wild boar by determining the presence or
absence of a group of four (of the five antigens
used in the first and second aspects of the
invention) , or the presence or absence of an immune
response to each member of said group of four
antigens. The group of antigens consists of (i) an
MPB70 antigen, (ii) an MPB83 antigen, and (iii) an
Rv3616c antigen and (iv) a CFPlO antigen.
Accordingly, the invention further extends in a
third aspect to a method of diagnosis of
tuberculosis in a cervid or a suidae mammal, the
method comprising the steps:
providing a biological sample from said cervid or
suidae mammal; determining the presence or absence
of, or an immune response to each of an Rv3616
antigen, an MPB70 antigen, an MPB83 antigen, and a
CFPlO antigen; wherein the identification of the
presence of one or more, for example two or more, of
said antigens of said group of antigens, or of an
immune response thereto, is indicative of the
presence of tuberculosis infection in the cervid or
suidae mammal .
The invention also extends in a fourth aspect to an
assay method for the detection of the presence of
Mycobacterium, for example Mycobacterium bovis, in a
biological sample from a cervid or a suidae mammal,
the method comprising the steps:
providing a biological sample from said cervid or
suidae mammal; determining the presence or absence
of, or an immune response to each of an Rv3616
antigen, an MPB70 antigen, an MPB83 antigen, and a
CFPlO antigen; wherein the identification of the
presence of one or more, for example two or more, of
said antigens, or of an immune response to one or
more, for example two or more, of said antigens, is
indicative of the presence of tuberculosis infection
in the cervid or suidae mammal.
In one embodiment of the third or fourth aspects of
the invention, the method does not comprise the
determination of the presence or absence of any
mycobacterial antigen, or an immune response
thereto, other than of or to an Rv3616 antigen, an
MPB70 antigen, an MPB83 antigen, and a CFPlO
antigen .
In one embodiment of the third or fourth aspect of
the invention, wherein the animal is a cervid, the
identification of the presence of one of said
antigens of said group of antigens, or of an immune
response thereto, is indicative of the presence of
tuberculosis infection in the cervid.
In one embodiment of the third or fourth aspect of
the invention wherein the animal is a suidae mammal,
the identification of the presence of two of said
antigens of said group of antigens, or of an immune
response thereto, is indicative of the presence of
tuberculosis infection in the suidae mammal.
In a particular embodiment of the third or fourth
aspects of the invention, the animal is a wild boar.
A number of wild mammals are considered reservoirs
for TB infection. For example, badgers are
considered as a significant source of TB infection
for cattle and, as a result, are often culled to
prevent TB spread to cattle. However, this means of
control of TB infection is controversial. A test
which could reliably identify TB infection in
badgers (and other host animals, which may act as
reservoirs of infection) would therefore be
invaluable in establishing whether or not individual
animals, sets or populations thereof are indeed a
threat to other species and thus save unnecessary
culling. To date, however, a test which can
reliably identify infection in animals such as
badgers is not available. Typical tests have a
reported sensitivity of less than 50% when assessing
field samples (Chambers et al J Clin Microbiol. 2008
Apr;46 (4) :1498-500) .
The methods of the present invention achieve
considerably higher sensitivity than known tests for
use in diagnosis of TB infection in animals such as
badgers. Thus, in one embodiment of the invention,
the mammal is a "reservoir" animal , for example a
badger. In the context of the present invention, a
"reservoir" animal is any non-human animal which may
carry or be infected with tuberculosis and which may
act as a source of infection of tuberculosis to
domesticated livestock. Such reservoir animals
include, in addition to badgers, white tail deer,
possums, elephant and zoo/safari park animals.
Moreover, the inventors have determined that a
considerable improvement in sensitivity may be
achieved over known reservoir animals, e.g. badger,
TB diagnostic assays by testing for the presence or
absence of, or an immune response to each of a MPB70
antigen, an Rv3616c antigen and a MPB83 antigen.
Accordingly, in a fifth aspect of the invention,
there is provided a method of diagnosis of
tuberculosis in a mammal, the method comprising the
steps :
providing a biological sample from said mammal; and
determining the presence or absence of, or an
immune response to an Rv3616 antigen, an MPB70
antigen, and an MPB83 antigen, wherein the
identification of the presence of one or more of
said antigens of said group of antigens, or of an
immune response thereto, is indicative of the
presence of tuberculosis infection in the mammal.
In a particular embodiment of this aspect of the
invention, the method does not comprise the
determination of the presence or absence of any
mycobacterial antigen, or an immune response
thereto, other than Rv3616 antigen, an MPB70
antigen, and an MPB83 antigen. In another
embodiment of this aspect of the invention, the
method employs determining the presence or absence
of CFP-IO, optionally in the absence of
determination of the presence or absence of any
other mycobacterial antigen, or an immune response
thereto, other than Rv3616 antigen, an MPB70
antigen, an MPB83 antigen, and a CFP-IO antigen.
In one embodiment of the fifth aspect of the
invention, the mammal is a "reservoir" mammal. In a
particular embodiment, the mammal is a badger.
In the present application, unless the context
demands otherwise, references to tuberculosis should
be taken to refer to any tuberculosis, for example
human tuberculosis, non-human animal tuberculosis,
avian tuberculosis or a para-tuberculosis disease,
such as Johne's disease.
Unless the context demands otherwise (for example
where reference is made to an MPB70 antigen and a
pepl (MPB70) antigen within the same context),
reference to an MPB70 antigen should be understood
to encompass an MPB70 antigen having the sequence
shown as SEQ ID NO: 6 or a pepl (MPB70) antigen
having the sequence shown as SEQ ID NO: 7 , or both.
In one embodiment of the invention, the presence or
absence of an immune response to both an MPB70
antigen having the sequence shown as SEQ ID NO: 6
and a pepl (MPB70) antigen having the sequence shown
as SEQ ID NO: 7 are determined. The combination of
use of the pepl MPB70 peptide together with the
recombinant MPB70 protein allows the identification
of antibodies to both linear and conformational
epitopes .
Unless the context demands otherwise, reference to
Mycobacterium should be taken to refer to any
Mycobacterium. In one embodiment, the Mycobacterium
is Mycobacterium tuberculosis . In another embodiment
the Mycobacterium is Mycobacterium bovis. In another
embodiment, the Mycobacterium is Mycobacterium
avium. In another embodiment, the Mycobacterium is
Mycobacterium paratuberculosis . In another
embodiment, the Mycobacterium is Mycobacterium
caprae.
Any suitable biological sample may be used in the
methods of the invention. Suitable biological
samples include but are not limited to whole blood,
serum, plasma, saliva, cerebrospinal fluid, urine
and tissue samples.
In the methods of the invention, the presence of
particular antigens or an immune response thereto
may be determined using any means known in the art,
either directly or indirectly. For example, in one
embodiment, the presence of the antigen in the
sample is determined; alternatively or additionally
the presence of an antibody specific to said antigen
is determined; alternatively, or additionally, the
presence of a nucleic acid encoding said antibody or
said antigen is determined.
The identification by the inventors of the
particular selection of mycobacterial antigens which
are particularly immunogenic, which are widely
prevalent across geographical areas, and which
moreover, cover each of the different stages of the
TB life cycle enables the use of these polypeptides
in the preparation of novel vaccines against
tuberculosis. Such vaccines should provide a
vaccinated animal with a sustained resistance to
infection .
Accordingly, in a sixth aspect of the present
invention, there is provided a vaccine or
immunomodulator for use in the vaccination of
mammals , wherein the vaccine comprises (i)an Rv3616
antigen, (ii) an MPB70 antigen, (iii) an MPB70
linear epitope, for example PEPl (MPB70) (iv) an
MPB83 antigen, and (v) at least one of (a) a CFPlO
antigen and (b) an ESAT 6 antigen.
In one embodiment of the sixth aspect of the
invention, the vaccine does not comprise an ESAT 6
antigen. Optionally, the vaccine does not comprise a
mycobacterial antigen other than the Rv3616 antigen,
MPB70 antigen, MPB70 linear epitope, for example
PEPl (MPB70), MPB83 antigen, and CFPlO antigen
and/or ESAT 6 antigen.
Given the demonstration of the high sensitivity of
detection of TB infection in reservoir animals such
as badgers when testing for the presence or absence
of, or an immune response to, MPB70, Rv3616c and
MPB83, it is believed that vaccines comprising at
least these three antigens would be expected to have
a significant effect on protecting against TB
infection in such reservoir animals.
Thus, in a seventh aspect of the present invention,
there is provided a vaccine or immunomodulator for
reservoir animals, said vaccine or immunomodulator
comprising an Rv3616 antigen, an MPB70 antigen, and
an MPB83 antigen.
In one embodiment, the vaccine does not comprise a
mycobacterial antigen other than the Rv3616 antigen,
the MPB70 antigen, and the MPB83 antigen.
In an alternative embodiment, the vaccine further
comprises a CFPlO antigen. In such an embodiment,
the vaccine optionally does not comprise a
mycobacterial antigen other than an Rv3616 antigen,
an MPB70 antigen, an MPB83 antigen and a CFPlO
antigen.
In one embodiment of the sixth or seventh aspects of
the invention, the vaccine is a vaccine against
tuberculosis .
In an alternative embodiment of the sixth or seventh
aspects of the invention, one or more of said
polypeptides are used in a vaccine as an adjuvant.
In a eighth aspect of the invention, there is
provided a method of providing immunity in an animal
against tuberculosis, the method comprising
administering to said animal a vaccine according to
the sixth aspect or the seventh aspect of the
invention.
In a ninth aspect of the invention, there is
provided (i)an Rv3616 antigen, (ii) an MPB70
antigen, (iii) an MPB70 linear epitope, for example
PEPl (MPB70) (iv) an MPB83 antigen, and (v) at least
one of (a) a CFPlO antigen and (b) an ESAT 6 antigen
for use in a vaccine against tuberculosis.
In a tenth aspect of the invention, there is
provided the use of (i)an Rv3616 antigen, (ii) an
MPB70 antigen, (iii) an MPB70 linear epitope, for
example PEPl (MPB70) (iv) an MPB83 antigen, and (v)
at least one of (a) a CFPlO antigen and (b) an ESAT
6 antigen in the preparation of a vaccine against
tuberculosis.
In an eleventh aspect of the invention, there is
provided an Rv3616 antigen, an MPB70 antigen, an
MPB83 antigen, and a CFPlO antigen for use in a
vaccine against tuberculosis.
In a twelfth aspect of the invention, there is
provided the use of an Rv3616 antigen, an MPB70
antigen, an MPB83 antigen, and a CFPlO antigen in
the preparation of a vaccine against tuberculosis.
In each of the ninth, tenth, eleventh and twelfth
aspects of the invention, the vaccine optionally
comprises no other mycobacterial antigens.
In an thirteenth aspect, the invention provides a
diagnostic kit for the diagnosis of the presence of
tuberculosis in a subject, said kit comprising:
(i)an Rv3616 antigen, (ii) an MPB70 antigen, (iii)
an MPB70 linear epitope, for example PEPl (MPB70)
(iv) an MPB83 antigen, and (v) at least one of (a) a
CFPlO antigen and (b) an ESAT 6 antigen.
In an embodiment of the thirteenth aspect, the kit
further comprises at least one of an Rvl573 antigen,
an Rvl580c antigen, and an Rvl585c antigen.
In a fourteenth aspect of the invention, there is
provided a diagnostic kit for the diagnosis of the
presence of tuberculosis in a biological sample,
said kit comprising:
(i) an antibody molecule with binding specificity
for an Rv3616 antigen, (ii) an antibody molecule
with binding specificity for an MPB70 antigen, (iii)
an antibody molecule with binding specificity for an
MPB70 linear epitope, for example PEPl (MPB70) (iv)
an antibody molecule with binding specificity for an
MPB83 antigen, and (v) at least one of (a) an
antibody molecule with binding specificity for a
CFPlO antigen and (b) an antibody molecule with
binding specificity for an ESAT 6 antigen.
In one embodiment of the fourteenth aspect, the kit
does not comprise an antibody molecule with binding
specificity for any mycobacterial antigen other than
for a Rv3616 antigen, an MPB70 antigen, an MPB70
linear epitope, for example PEPl (MPB70), an MPB83
antigen, a CFPlO antigen or an ESAT 6 antigen.
In an embodiment of the fourteenth aspect, wherein
the kit comprises (a) an antibody molecule with
binding specificity for a CFPlO antigen, but does
not comprise (b) an antibody molecule with binding
specificity for an ESAT-6 antigen.
In an embodiment of the fourteenth aspect, the kit
further comprises at least one of the antibody
molecules selected from the group consisting of an
antibody molecule with binding specificity for an
Rvl573 antigen, an antibody molecule with binding
specificity for an Rvl580c antigen, and an antibody
molecule with binding specificity for an Rvl585c
antigen.
In a fifteenth aspect of the invention, there is
provided a diagnostic kit for the diagnosis of the
presence of tuberculosis in a reservoir animal such
as a badger, said kit comprising an Rv3616 antigen,
an MPB70 antigen, and an MPB83 antigen.
In one embodiment, the diagnostic kit further
comprises a CFPlO antigen. In another embodiment,
the kit does not comprise another mycobacterial
antigen .
In a sixteenth aspect of the invention, there is
provided a diagnostic kit for the diagnosis of the
presence of tuberculosis in a biological sample from
a reservoir animal such as a badger, said kit
comprising: an antibody molecule with binding
specificity for an Rv3616 antigen, an antibody
molecule with binding specificity for an MPB70
antigen, and an antibody molecule with binding
specificity for an MPB83 antigen.
In one embodiment of the sixteenth aspect of the
invention, the diagnostic kit further comprises an
antibody molecule with binding specificity for CFPlO
antigen. In another embodiment, the kit does not
comprise an antibody molecule with binding
specificity for a mycobacterial antigen other than
for a Rv3616 antigen, a MPB70 antigen, or a MPB83
antigen. In another embodiment, the kit does not
comprise an antibody molecule with binding
specificity for a mycobacterial antigen other than
for a Rv3616 antigen, a MPB70 antigen, a MPB83
antigen, or a CFP-IO antigen.
Preferred features of each aspect of the invention
are as for each of the other aspects mutatis
mutandis .
Detailed Description
Polypeptides , Variants and Fragments
As described above, the inventors have identified a
number of tuberculosis antigens which may be used in
the diagnosis of tuberculosis, the differentiation
between strains of Mycobacteria, and/or preparation
of vaccines. The polypeptide sequences for each of
these antigens are provided in Table 1 . In one
embodiment of the invention, the full length antigen
sequences are used.
In one embodiment of the invention, the antigens for
use in the invention consist of polypeptides
consisting of the amino acid sequence shown as any
one of SEQ ID N0:l to SEQ ID NO: 16.
However, the present invention is not limited to the
use of polypeptides having such specific sequences
of the polypeptides or disclosed herein but also
extends to fragments or variants of such full length
polypeptides. Thus, unless the context demands
otherwise, where reference is made to an Rv3616c
antigen, it should be understood to encompass an
Rv3616c antigen consisting of the amino acid
sequence shown as SEQ ID NO: 1 , or a variant or
fragment thereof, where reference is made to an
MPB70 antigen, it should be understood to encompass
an MPB70 antigen consisting of the amino acid
sequence shown as SEQ ID NO: 7 , or a variant or
fragment thereof, where reference is made to an
MPB83 antigen, it should be understood to encompass
an MP83 antigen consisting of the amino acid
sequence shown as SEQ ID NO: 8 , or a variant or
fragment thereof, where reference is made to an
ESAT6 antigen, it should be understood to encompass
an ESAT6 antigen consisting of the amino acid
sequence shown as SEQ ID NO: 9 , or a variant or
fragment thereof, where reference is made to a CFP-
10 antigen, it should be understood to encompass an
CFP-IO antigen consisting of the amino acid sequence
shown as SEQ ID NO: 10, or a variant or fragment
thereof, where reference is made to a Rvl573
antigen, it should be understood to encompass an
Rvl573 antigen consisting of the amino acid sequence
shown as SEQ ID NO: 14, or a variant or fragment
thereof, where reference is made to a Rvl580c
antigen, it should be understood to encompass an
Rvl580c antigen consisting of the amino acid
sequence shown as SEQ ID NO: 15, or a variant or
fragment thereof, where reference is made to a
Rvl585c antigen, it should be understood to
encompass an Rvl585c antigen consisting of the amino
acid sequence shown as SEQ ID NO: 16, or a variant
or fragment thereof
For example, with respect to Rv3616c, specific
examples of particular fragments which may be used
are provided as SEQ ID NOs 2-5. Likewise, with
respect to CFP-IO, specific examples of particular
fragments which may be used are provided as SEQ ID
NOs 10-13. Variant polypeptide sequences in which
one or more amino acid residues are modified may
also be used as the polypeptides/antigens in the
invention. For example such variants may be useful
in the preparation of vaccines or the raising of
antibodies which may be used in kits of the
invention. Modifications may involve insertion,
addition, deletion and/or substitution of one or
more amino acids. The modified amino acid residues
in the amino acid sequences of the variant are
preferably 30% or less, more preferably 20% or less,
most preferably 10% or less, within the entire
polypeptide. Such variants may be provided using the
teaching of the present application and techniques
known in the art. Preferably such variants involve
the insertion, addition, deletion and/or
substitution of 15 or fewer amino acids, more
preferably of 10 or fewer, even more preferably of 5
or fewer, most preferably of 1 or 2 amino acids
only.
Amino acid substitutions which do not essentially
alter biological and immunological activities, have
been described, e . g . by Neurath et al in "The
Proteins" Academic Press New York (1979) . Amino acid
replacements between related amino acids or
replacements which have occurred frequently in
evolution are, inter alia, Ser/Ala, Ser/Gly, Asp/Gly,
Asp/Asn, Ile/Val (see Dayhof, M . D . , Atlas of
protein sequence and structure, Nat. Biomed. Res.
Found. , Washington D . C , 1978, vol. 5 , suppl . 3 ) .
Other amino acid substitutions may include but are
not limited to Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr,
Ser/Asn, Ala/Val, Thr/Phe, Ala/Pro, Lys/Arg, Leu/Ile,
Leu/Val and Ala/Glu.
In preferred embodiments , a variant or fragment
retains the immune reactivity of the polypeptide
having the amino acid sequence shown as any one of
SEQ ID N0:l to SEQ ID NO: 16, of which it is a
variant or fragment.
For the avoidance of any doubt, in the present
application, where reference is made to the presence
of two or more antigens selected from a list, it
should be understood that reference is being made to
two or more different antigens i.e. each having a
different amino acid sequence.
Furthermore, for the avoidance of any doubt, in the
present application, unless the context demands
otherwise, where reference is made to the
determination of the presence or absence of two or
more polypeptides/antigens selected from a list, or
the presence or absence of an immune response
thereto, it should be understood that such a
statement encompasses the determination of the
presence or absence of two or more of said
polypeptides/antigens selected from the list or the
determination of the presence or absence of an
immune response to two or more of said
polypeptides/antigens or indeed a mixture thereof
i.e. the determination of the presence or absence of
one or more polypeptides/antigens selected from the
list combined with the determination of an immune
response to one or more other polypeptides/antigens
selected from the list.
Furthermore for the avoidance of any doubt, where
reference is made to MPB70 or variants thereof and
pepl (MPB70) together, pepl (MPB70) should not be
considered as an MPB70 variant.
Antibody molecules
In the context of the present invention, an
"antibody molecule" should be understood to refer to
an immunoglobulin or part thereof or any polypeptide
comprising a binding domain which is, or is
homologous to, an antibody binding domain.
Antibodies include but are not limited to
polyclonal, monoclonal, monospecific, polyspecific
antibodies and fragments thereof and chimeric
antibodies comprising an immunoglobulin binding
domain fused to another polypeptide.
Intact (whole) antibodies comprise an immunoglobulin
molecule consisting of heavy chains and light
chains, each of which carries a variable region
designated VH and VL, respectively. The variable
region consists of three complementarity determining
regions (CDRs, also known as hypervariable regions)
and four framework regions (FR) or scaffolds. The
CDR forms a complementary steric structure with the
antigen molecule and determines the specificity of
the antibody.
Fragments of antibodies may retain the binding
ability of the intact antibody and may be used in
place of the intact antibody. Accordingly, for the
purposes of the present invention, unless the
context demands otherwise, the term "antibodies"
should be understood to encompass antibody
fragments. Examples of antibody fragments include
Fab, Fab', F(ab')2, Fd, dAb, and Fv fragments,
scFvs, bispecific scFvs, diabodies, linear
antibodies (see US patent 5,641,870, Example 2 ;
Zapata et al ., Protein Eng 8 (10): 1057-1062
[1995]); single-chain antibody molecules; and
multispecif ic antibodies formed from antibody
fragments .
The Fab fragment consists of an entire L chain (VL
and CL), together with VH and CHl. Fab' fragments
differ from Fab fragments by having an additional
few residues at the carboxy terminus of the CHl
domain including one or more cysteines from the
antibody hinge region. The F(ab')2 fragment
comprises two disulfide linked Fab fragments. Fd
fragments consist of the VH and CHl domains. Fv
fragments consist of the VL and VH domains of a
single antibody. Single-chain Fv (scFv) fragments
are antibody fragments that comprise the VH and VL
domains connected by a linker which enables the scFv
to form an antigen binding site (see Pluckthun in
The Pharmacology of Monoclonal Antibodies, vol. 113,
Rosenburg and Moore eds ., Springer-Verlag, New York,
pp. 269-315 (1994) . Diabodies are small antibody
fragments prepared by constructing scFv fragments
with short linkers (about 5-10 residues) between the
VH and VL domains such that inter-chain but not
intra-chain pairing of the V domains is achieved,
resulting in a multivalent fragment, i.e. a fragment
having two antigen-binding sites (see, for example,
EP 404 097; WO 93/11161; and Hollinger et al ., PNAS.
USA, 90: 6444-6448 (1993)).
Further encompassed by fragments are individual
CDRs. The CDRs may be carried on a framework
structure comprising an antibody heavy or light
chain sequence or part thereof. Preferably such
CDRs are positioned in a location corresponding to
the position of the CDR (s) of naturally occurring VH
and VL domains. The positions of such CDRs may be
determined as described in Rabat et al, Sequences of
Proteins of Immunological Interest, US Dept of
Health and Human Services, Public Health Service,
Nat'l Inst, of Health, NIH Publication No. 91-3242,
1991 and online at www.kabatdatabase.com
http ://immuno .bme .nwu .edu . Furthermore,
modifications may alternatively or additionally be
made to the Framework Regions of the variable
regions. Such changes in the framework regions may
improve stability and reduce immunogenicity of the
antibody.
The antibody molecules for use in the present
invention extend, for example, to any other antibody
which specifically binds a polypeptide identified
herein as inducing a strong immune response i.e. an
antibody molecule which retains binding specificity
for a polypeptide consisting of amino acid sequence
shown as any one of SEQ ID NOs :1 to 16.
Antibody molecules for use in the invention herein
include "chimeric" antibodies in which a portion of
the heavy and/or light chain is identical with or
homologous to corresponding sequences in antibodies
derived from a particular species or belonging to a
particular antibody class or subclass, while the
remainder of the chain (s) is identical with or
homologous to corresponding sequences in antibodies
derived from another species or belonging to another
antibody class or subclass, as well as fragments of
such antibodies, so long as they exhibit the desired
biological activity (see US 4,816,567; and Morrison
et al., PNAS. USA, 81: 6851-6855 (1984)). Chimeric
antibodies of interest herein include "primatized"
antibodies comprising variable domain antigen-
binding sequences derived from a non-human
primate (e.g. Old World Monkey, Ape etc), and human
constant region sequences.
Antibody molecules for use in the present invention
may be produced in any suitable way, either
naturally or synthetically. Such methods may
include, for example, traditional hybridoma
techniques (Kohler and Milstein (1975) Nature, 256
:495-499), recombinant DNA techniques (see e.g. US
4,816, 567), or phage display techniques using
antibody libraries (see e.g. Clackson et al. (1991)
Nature, 352: 624-628 and Marks et al. (1992) Bio/
Technology, 10: 779-783). Other antibody production
techniques are described in Antibodies: A Laboratory
Manual, eds . Harlow et al ., Cold Spring Harbor
Laboratory, 1988.
Traditional hybridoma techniques typically involve
the immunisation of a mouse or other animal with an
antigen in order to elicit production of lymphocytes
capable of binding the antigen. The lymphocytes are
isolated and fused with a myeloma cell line to form
hybridoma cells which are then cultured in
conditions which inhibit the growth of the parental
myeloma cells but allow growth of the antibody
producing cells. The hybridoma may be amenable to
genetic mutation, which may or may not alter the
binding specificity of antibodies produced.
Synthetic antibodies can be made using techniques
known in the art (see, for example, Knappik et al,
J . MoI. Biol. (2000) 296, 57-86 and Krebs et al, J .
Immunol. Meth. (2001) 2154 67-84).
Modifications may be made in the VH, VL or CDRs of
the antibody molecules, or indeed in the FRs using
any suitable technique known in the art. For
example, variable VH and/or VL domains may be
produced by introducing a CDR, e.g. CDR3 into a VH
or VL domain lacking such a CDR. Marks et al.
(1992) Bio/ Technology, 10: 779-783 describe a
shuffling technique in which a repertoire of VH
variable domains lacking CDR3 is generated and is
then combined with a CDR3 of a particular antibody
to produce novel VH regions. Using analogous
techniques, novel VH and VL domains comprising CDR
derived sequences of the present invention may be
produced.
Alternative techniques of producing antibodies for
use in the invention may involve random mutagenesis
of gene(s) encoding the VH or VL domain using, for
example, error prone PCR (see Gram et al, 1992, PNAS
89 3576-3580. Additionally or alternatively, CDRs
may be targeted for mutagenesis e.g. using the
molecular evolution approaches described by Barbas
et al 1991 PNAS 3809-3813 and Scier 1996 J MoI Biol
263 551-567. Having produced such variants,
antibodies and fragments they may be tested for
binding to a Mycobacterium, for example
Mycobacterium bovis.
The antibodies for use in the invention may comprise
further modifications. For example the antibodies
can be glycosylated, pegylated, or linked to albumin
or a nonproteinaceous polymer.
The antibody molecules for use in the invention may
be labelled. Labels which may be used include
radiolabels, enzyme labels such as horseradish
peroxidase or alkaline phosphatase, or biotin.
Nucleic Acid
Nucleic acid for use in the present invention may
comprise DNA or RNA. It may be produced
recombinantly, synthetically, or by any means
available to those in the art, including cloning
using standard techniques.
The nucleic acid may be inserted into any
appropriate vector. In one embodiment the vector is
an expression vector and the nucleic acid is
operably linked to a control sequence which is
capable of providing expression of the nucleic acid
in a host cell. A variety of vectors may be used.
For example, suitable vectors may include viruses
(e. g . vaccinia virus, adenovirus, etc .),
baculovirus) ; yeast vectors, phage, chromosomes,
artificial chromosomes, plasmids, or cosmid DNA.
The vectors may be used to introduce the nucleic
acids into a host cell. A wide variety of host cells
may be used for expression of the nucleic acid.
Suitable host cells for use in the invention may be
prokaryotic or eukaryotic. They include bacteria,
e.g. E . coli, yeast, insect cells and mammalian
cells. Mammalian cell lines which may be used
include Chinese hamster ovary cells, baby hamster
kidney cells, NSO mouse melanoma cells, monkey and
human cell lines and derivatives thereof and many
others.
A host cell strain that modulates the expression of,
modifies, and/or specifically processes the gene
product may be used. Such processing may involve
glycosylation, ubiquitination, disulfide bond
formation and general post-translational
modification .
For further details relating to known techniques and
protocols for manipulation of nucleic acid, for
example, in preparation of nucleic acid constructs,
mutagenesis, sequencing, introduction of DNA into
cells and gene expression, and analysis of proteins,
see, for example, Current Protocols in Molecular
Biology, 5th ed., Ausubel et al. eds ., John Wiley &
Sons, 2005 and, Molecular Cloning: a Laboratory
Manual: 3rd edition Sambrook et al., Cold Spring
Harbor Laboratory Press, 2001.
Diagnostic Methods, Assays and Kits
The invention may be used in the diagnosis of a
variety of conditions and disorders associated with
tuberculosis. These include infection with
Mycobacterium bovis, Mycobacterium avium and human
mycobacterium and para-tuberculosis diseases such as
Johne's disease.
In using the methods of the invention to identify
the infection with a mycobacterial strain, either as
current or previous infection, the presence or
absence of immunogenic polypeptides, or the presence
or absence of an immune response to said
polypeptides is determined from a biological sample.
Any suitable biological sample may be used. For
example, the biological sample may be a biological
fluid, such as sputum, saliva, plasma, blood, urine
or sperm, or a tissue, such as a biopsy of a tissue.
Diagnostic and assay means of detecting the presence
of polypeptides or immune responses to said
polypeptides are known in the art. For example, the
presence of the polypeptides may be detected by use
of antibodies specific to said polypeptides.
Alternatively, using standard techniques in the art,
the presence of nucleic acids encoding the
polypeptide or indeed an antibody specific to said
polypeptide may be used. Further, the presence of
antibodies specific to said polypeptides may be used
to determine the presence of an immune response to
said polypeptide.
Techniques which may be employed include but are not
limited to ELISA, Immunohistochemistry, Electron
Microscopy, Latex agglutination, Immuno Blotting,
immunochromatography, immunochips, lateral flow
immunoassays and Dip Stick Immuno testing.
The ELISA test (enzyme linked immunoenzymatic assay)
is frequently used for serological diagnosis. This
method allows the identification and quantification
of antigens or antibodies in biological fluids. The
conventional ELISA consists in the detection of the
complex antibody-antigen by a second antibody
(against the antibody that reacts with the antigen)
conjugated to an enzymatic activity (peroxidase,
alkaline phosphatase and others) .
In the latex agglutination assay, the antigen
preparation is affixed to latex beads. The
biological sample is then incubated directly on a
slide with the latex particles. In a short time the
reaction is examined for the presence of cross-
linked, or agglutinated, latex particles indicating
the presence of antibodies to polypeptides in the
sample.
Immunochips may used to determine the presence of
the specific Mycobacterium antigens. Generally, the
specific antibodies to the antigens are immobilised
on a transducer, e.g. electrodes, caloric meter,
piezoelectric crystal, surface plasmon resonance
transducer, surface acoustic resonance transducer or
other light detecting device. The binding of
antigens in the biological sample to the immobilised
specific antibody is detected by a change in
electric signal.
As described above, the presence of immunogenic
antigens may be detected by detecting nucleic acids
encoding the antigen or encoding antibodies raised
against the antigen. Such techniques are well known
in the art. For example, where large amounts of DNA
are available, genomic DNA may be used directly.
Alternatively, the region of interest is cloned into
a suitable vector and grown in sufficient quantity
for analysis. The nucleic acid may be amplified by
conventional techniques, such as the polymerase
chain reaction (PCR) (Saiki, et al . (1985) Science
239:487). Primers may be used to amplify sequences
encoding the polypeptide of interest. Optionally, a
detectable label, for example a fluorochrome, biotin
or a radioactive label may be used in such an
amplification reaction. The label may be conjugated
to one or both of the primers. Alternatively, the
pool of nucleotides used in the amplification is
labeled, so as to incorporate the label into the
amplification product.
The sample nucleic acid, e.g. amplified or cloned
may be analysed using any suitable method known in
the art. For example, the nucleic acid may be
sequenced by dideoxy or other methods, and the
sequence of bases compared to the deleted sequence.
Hybridization with the variant sequence may also be
used to determine its presence, by Southern blots,
dot blots, etc. The hybridization pattern of a
control and variant sequence to an array of
oligonucleotide probes immobilized on a solid
support, as described in WO95/35505, may be used as
a means of detecting the presence or absence of a
sequence .
In one embodiment, the kit contains an antigen
preparation prepared as described above and then
fixed onto a solid support for use in a serological
assay. The kit may also contain an explanatory note
on how to proceed.
In one embodiment, the assay is in a dip stick or
test strip format. Such assays typically employ a
solid support medium, which is able to bind target
substances such as proteins, for example protein
antigens. In use, the test strip is exposed to a
sample, for example serum, such that antibodies in
the serum may bind target substances such as
antigens on the test strip. After washing, the dip
stick/test strip is exposed to a labelled probe
which binds the bound antibody of interest, with
binding typically visualised by means of further
incubation with a visualisable substrate, for
example a chromogenic substrate.
In a further embodiment, the assay of the invention
is provided as a lateral flow immunoassay. Such
devices are well known in the art. Lateral flow
immunoassay devices typically employ a microporous
element along which a sample may flow laterally, the
device having a capture region for binding an
analyte of interest in the sample. Generally, the
lateral flow device has an application zone, to
which a sample is applied, a conjugate zone,
containing a mobile reporter conjugate, which is
typically a visually observable reporter e.g.
colloidal gold conjugated to an antibody directed
against the analyte and a capture region comprising
a capture agent which binds the analyte. In use,
the sample is applied to the application zone and
flows along a strip to a first region, at which the
reporter conjugate binds the analyte. Thereafter,
movement of the reporter conjugate/analyte complex
to the capture region results in capture of the
complex at that region. Uncomplexed reporter
conjugate does not bind at the capture region. By
determining the amount of visually detectable signal
at the capture region, the presence of analyte in a
sample may be determined. Variants of such kits are
well known in the art.
In one embodiment of the invention, the methods,
assays and kits of the invention comprise or use an
assay in which the presence or absence of a number
of antigens or an immune response thereto is
analysed simultaneously, i.e. using a multiplex
based assay. Any suitable multiplex assay may be
used. For example, arrays of different tuberculosis
antigens may be provided in microplate wells and a
sample mixed with reporter antibodies in the wells.
Other multiplex based methods may involve protein
arrays placed on a matrix, with the response to
individual proteins on the solid-phase array
assayed. The use of such multiplex techniques
enables the rapid identification of the presence or
absence of a plurality of target antigens (or
antibodies) during a single run of the analysis. A
suitable multiplex system which may be used is that
described by Whelan et al (Clinical and Vaccine
Immunology, 2008, 1834-1838) .
The inventors have developed a multiplex technique
in which a plurality of different antigens, for
example up to 25, are spotted in a single well of a
96 well plate. The inventors have shown that high
sensitivity of reaction with each of the antigens
tested was possible in the multiplex reactant
mixture despite the necessary requirement of a
single buffer being used for each of the plurality
of antigen- antibody reactions in a single well.
Using such a plate, up to 96 samples, each from a
different animal, may be tested on a single plate
with the each samples reactivity with each of the
antigens measured simultaneously. Such a technique
therefore enables the rapid analysis of infection
with, for example, tuberculosis, in a large number
of animals simultaneously.
Moreover, the inventors have surprisingly found that
the advantages of such a system for the
determination of tuberculosis infection is not just
with respect to the convenience of being able to
test many different antigens in many different
samples simultaneously. The inventors have also
demonstrated that the multiplex platform provided
higher sensitivity and specificity than that
obtained using conventional assays such as lateral
flow assays and ELISA.
Accordingly, in a further aspect of the invention,
there is provided a multiplex method of diagnosis of
tuberculosis in an animal, the method comprising the
steps :
providing a substrate on which is immobilised a
plurality of different antigens, wherein said
antigens comprise (i)an Rv3616 antigen, (ii) an
MPB70 antigen, (iii) an MPB70 linear epitope, for
example PEPl (MPB70) (iv) an MPB83 antigen, and (v)
at least one of (a) a CFPlO antigen and (b) an ESAT
6 antigen,
bringing into contact with said substrate a
biological sample from an animal,
identifying the presence or absence of binding of
antibodies from said sample with said antigens,
wherein the determination of binding is indicative
of the presence of tuberculosis infection in the
animal .
In one embodiment, the substrate is a microplate.
In one such embodiment, a plurality of different
antigens are immobilised in a single well of a
plate. In one embodiment of this aspect of the
invention, the plurality of antigens comprises (i)an
Rv3616 antigen, (ii) an MPB70 antigen, (iii) an
MPB70 linear epitope, for example PEPl (MPB70) (iv)
an MPB83 antigen, and (v) at least one of (a) a
CFPlO antigen and (b) an ESAT 6 antigen or fragments
or variants thereof.
In a further aspect of the invention, there is
provided a multiplex method of diagnosis of
tuberculosis in an animal, the method comprising the
steps :
providing a substrate to which is attached a
plurality of different antibody molecules, wherein
said antibody molecules comprise i ) an antibody
molecule with binding specificity for an Rv3616
antigen, (ii) an antibody molecule with binding
specificity for an MPB70 antigen, (iii) an antibody
molecule with binding specificity for an MPB70
linear epitope, for example PEPl (MPB70) (iv) an
antibody molecule with binding specificity for an
MPB83 antigen, and (v) at least one of (a) an
antibody molecule with binding specificity for a
CFPlO antigen and (b) an antibody molecule with
binding specificity for an ESAT 6 antigen;
bringing into contact with said substrate a
biological sample from an animal,
identifying the presence or absence of binding of
antigens from said sample with said antibody
molecules,
wherein the determination of binding is indicative
of the presence of tuberculosis infection in the
animal .
In one embodiment, the substrate is a microplate.
In one such embodiment, a plurality of different
antibody molecules are immobilised in a single well
of a plate. In one embodiment of this aspect of the
invention, the plurality of antibodies comprises i )
an antibody molecule with binding specificity for an
Rv3616 antigen, (ii) an antibody molecule with
binding specificity for an MPB70 antigen, (iii) an
antibody molecule with binding specificity for an
MPB70 linear epitope, for example PEPl (MPB70) (iv)
an antibody molecule with binding specificity for an
MPB83 antigen, and (v) at least one of (a) an
antibody molecule with binding specificity for a
CFPlO antigen and (b) an antibody molecule with
binding specificity for an ESAT 6 antigen..
The kit can be used to perform the methods of the
invention described above.
Vaccines
As described above, the present invention also
extends to vaccines for use in protecting against
tuberculosis and tuberculosis-associated diseases.
One way of making a vaccine according of or for use
in the invention is by biochemical purification of
the immunogenic polypeptides from bacteria.
Alternatively, expression products of the genes
encoding the polypeptides according to the invention
may be used in vaccines. Such vaccines based upon
the expression products of these genes can easily be
made by admixing one or more proteins with a
pharmaceutically acceptable carrier.
Alternatively, a vaccine according to the invention
can comprise live recombinant carriers, capable of
expressing the polypeptides according to the
invention .
Vaccines described above all contribute to active
vaccination, i.e. the host's immune system is
triggered by one or more proteins according to the
invention or immunogenic fragments thereof, to make
antibodies against these proteins.
Alternatively, such antibodies can be raised in e.g.
rabbits or can be obtained from antibody-producing
cell lines. Such antibodies can then be administered
to the host animal. This method of vaccination,
passive vaccination, is the vaccination of choice
when an animal is already infected, and there is no
time to allow the natural immune response to be
triggered. It is also the preferred method for
vaccinating immune-compromised animals.
Therefore, one other form of this embodiment of the
invention relates to vaccines comprising antibodies
against one or more of the immunogenic polypeptides
used in the invention.
An alternative and efficient way of vaccination is
direct vaccination with DNA encoding the relevant
antigen. Direct vaccination with DNA encoding
proteins has been successful for many different
proteins. (As reviewed in e . g . Donnelly et al . ,
The Immunologist 2:20-26(1993)). Therefore, still
other forms of this embodiment of the invention
relate to vaccines comprising nucleic acid sequences
encoding a polypeptide as used in the invention or
immunogenic fragments thereof, and to vaccines
comprising DNA fragments that comprise such nucleic
acid sequences.
Still other forms of this embodiment relate to
vaccines comprising recombinant DNA molecules
according to the invention.
DNA vaccines can easily be administered through
intradermal application e . g . using a needle-less
injector .
Vaccines according to the present invention may
comprise a pharmaceutically acceptable carrier e . g .
sterile water, a sterile physiological salt
solution, or a buffer, and may also contain an
adjuvant.
The invention will now be described further in the
following non-limiting examples.
Example 1
The inventors have identified a panel of proteins
capable of strain identification (Table 1).
Methodology Multiplex Assays
Serum samples
Serum samples used in the study were obtained from
several sources. Blood samples were taken into
serum tubes (Vacuette, serum clot activator tubes,
Greiner-bio-one) , transported at room temperature
and then stored at 2-8 0C until processing.
Following centrifugation (300Og, 30 minutes at 2-
80C ) the serum was removed, aliquoted and stored at
-2O 0C .
Two sets of sera were obtained, one from a negative
sample bank including sera from herds of animals
with a known history of being free of Mbv. A third
group of sera were collected from animals that were
proven to be positive for Mbv infection at the time
of slaughter based on subsequent
histopat hological /bacteriological examination .
The fourth set of serum samples was part of an
infectivity study. The animals were non-vaccinated
and challenged via the intra-tracheal route with a
low dose of a virulent strain of Mbv (approximately
5,000 CFU). Sera were collected prior to challenge
and then at 2 , 5 , 10 and 17 weeks post infection
(PI) (data not shown) . A single intradermal
comparative cervical tuberculin test (SICCT) was
carried out prior to challenge and also during week
15 PI. All animals in the study had lesions typical
of a TB infection, and all animals at 17 weeks PI
were culture positive for Mbv.
Preparation of antigens
The genes encoding different TB proteins were
expressed in E . coli as N-terminal polyhistidine-
tagged (6X HIS) fusion proteins by Fusion Antibodies
Ltd. (Belfast) using the Fusion Expression
Technology (FET) platform. Recombinant proteins
were purified and polished to near homogeneity by
using Fusion Antibodies Ltd. three-step
chromatographic protocol. SDS-PAGE and western blot
analysis were performed on all purified and polished
recombinant TB proteins to confirm their level of
purity was greater than 99%. Synthetic peptides
were synthesised by Genosphere Biotechnologies
(France) to a purity of >80% (RP-HPLC at 220nm) .
Amino acid residues were added to peptides to
enhance the hydrophilicity of the peptides.
Lyophilised peptides were re-constituted to 2mg/ml
in sterile phosphate buffer saline pH 7.4 (Sigma
Aldrich, Dublin) and aliquots were prepared and
stored at -2O 0C . Antigen quantification was
performed using the micro BCA™ protein assay kit
(Pierce, Rockford, IL) .
Multiplex Antigen printing
Antigens used in the study were printed in each well
of a black polystyrene 96 well plate in a multiplex
planar array format by Quansys Biosciences, (Logan,
UT) . Optimization of the antigen printing was
carried out in conjunction with Enfer. Plates were
printed by Quansys Biosciences, (Logan, UT) and
testing of plates was carried out at Enfer
Scientific (Naas, Ireland) . Buffer mediated
alterations in spot deposition and morphology were
examined at Quansys Biosciences using an Alpha
Innotech 8900 imager workstation and a Nikon Diaphot
ELWD phase contrast inverted microscope. The
effects of differing buffers used for spotting were
screened for differential responses at Enfer. The
buffer selected gave the optimal pixel intensity
response with the optimal spot size/morphology on
the plates. Antigen coating concentrations
optimization was carried out at Enfer Scientific
(Naas, Ireland) using a series of coating titrations
printed by Quansys Biosciences in the optimized
printing buffer. Panels of antigens were printed
using the optimized printing protocol and buffers
and were used for sample testing. All plates were
shipped and stored at 2-8 0C . Plates were allowed to
warm to room temperature for 30 minutes prior to
use .
Multiplex immunoassay method
The assay method was developed in-house at Enfer
Scientific (Naas, Ireland) . Serum samples were
diluted 1:250 into sample dilution buffer (Enfer
Buffer A , Enfer Scientific, Naas, Ireland) and
mixed. 30µl of sample was added per well. Sample
dilution and plating was carried out using the
automated pipettor Tecan Genesis RSP 150. The plates
were incubated at room temperature with agitation
(900 rpm) for 30minutes. The plates were washed
with IX Enfer Wash Buffer (Enfer Scientific,
Ireland) six times and aspirated. The detection
antibody (polyclonal rabbit anti-bovine
immunoglobulin -HRP, Dako, Denmark) was prepared to
a dilution of 1:3000 in detection antibody dilution
buffer (Enfer Buffer B , Enfer Scientific, Naas,
Ireland) . After addition of 30µl of the detection
antibody to test wells, the plates were incubated at
room temperature for 15 minutes with agitation (900
rpm) . The plates were washed as above and 30µl of
substrate (50:50 dilution of substrate and diluent)
added per well (Chemilumenscent substrate and
diluent, Quansys Biosciences, Logan, Utah) . Signals
were captured over a 45 second exposure time using
Quansys Biosciences Imaging system (Quansys
Biosciences, Logan, Utah) . Images were saved as CR2
image files. Data were extracted from the captured
images using the Quansys Q-View Software™ Version
2.0. The data were compiled and analysed in a
custom made macro in Microsoft Excel (Enfer
Multiplex Macro, Version 1.0.1.0) .
Development of the multiplex chemiluminescent ELISA
Preliminary studies were conducted to optimize and
obtain uniform binding of each antigen using a
fluorescent tag. Following optimization of
spotting, tests were performed to determine lot to
lot variability in pixel intensity at Quansys
Biosciences based on the fluorescent tag
incorporated into the printing buffer. Plates were
tested and evaluated by Enfer for signal variation
using a panel of serum samples. Testing of the
plates with the detection antibody, with and without
sera from a panel of control sera from uninfected
cattle, showed that background noise in the system
in areas of the surface not coated with antigens was
on an average 779.3 relative light units (RLU) .
Optimisation of the printing concentration for all
antigens was carried out on a series of plates
printed based on a cohort of control sera. Optimal
printing concentrations were determined and used in
subsequent testing. Buffers, blocking agents and
assay conditions were further optimised on the
multiplex assay as well as optimisation of the
exposure time for signal capture. The optimal
exposure time was determined to be 45 seconds, this
giving the best signal to noise ratios with a cohort
of samples with varying signal intensities (data not
shown) .
A total of 1489 TB negative and 522 TB positive
animal sera were screened against the antigens
listed in Table 1 . The individual specificity and
sensitivity of all antigens were calculated based on
a range of cut offs before selecting individual
thresholds for each individual antigen. The
individual sensitivities of the antigens ranged from
5.4 - 95.0 % while individual specificities ranged
from 69.1 - 99.1%. Calculation of results was based
on a combinational approach to the data analysis on
results from all antigens for each sample.
Example 2 Identification of Panel of Antigens for
Diagnosis of TB in bovidae
The inventors analysed antigen expression from 447
cattle, which had been confirmed TB positive by
histopathology and culture methods, using 1489
cattle, which had been confirmed TB negative using
tuberculin skin tests, as the controls. The analysis
was carried out using the multiplex platform
described above in relation to Example 1 with the
following changes: 50µl of diluted sample and
diluted conjugate were added per well and 40µl of
prepared substrate was added per well instead of the
volumes recited in Example 1 . Moreover, the sample
incubation time was 90 minutes and the conjugate
incubation time was 30 minutes.
The inventors identified two panels of five
antigens, each panel of which when assayed together
enable diagnosis of tuberculosis infection with very
high sensitivity and selectivity. The assaying for
the presence of at least two of the five antigens
ESAT-6+Rv3616c+pepl (MPB70) +MPB83+MPB70 gave a
sensitivity of 93.7%, compared to 71.4% obtained
with ESAT-6+Rv3616c+pepl (MPB70) +MPB83, 25.5%
obtained using ESAT-6+Rv3616c +pepl (MPB70) . The
specificity obtained with ESAT-6+Rv3616c+pepl
(MPB70) +MPB83+MPB70 was 97.6%.
The assaying for the presence of at least two of the
five antigens CFP-10+Rv3616c+pepl (MPB70)
+MPB83+MPB70 gave a sensitivity of 97.8%. The
specificity obtained with CFP-10+Rv3616c+pepl
(MPB70) +MPB83+MPB70 was 97.6%.
The inventors then extended the study to another
member of the bovidae family. The inventors
analysed antigen expression from 62 goats, which had
been confirmed TB positive by tuberculin skin tests
and IFNg tests, using 31 goats, which had been
confirmed TB negative using tuberculin skin tests,
as the controls. The analysis was carried out using
the multiplex platform described above in relation
to Example 1 with the following changes: 50µl of
diluted sample and diluted conjugate were added per
well and 40µl of prepared substrate was added per
well instead of the volumes recited in Example 1;
moreover, the sample incubation time was 90 minutes
and the conjugate incubation time was 30 minutes;
samples were diluted to 1:1000, a different
conjugate (rabbit anti-goat IgG whole molecule,
peroxidise) was used with appropriate buffers and
the conjugate was diluted to 1:40,000.
The inventors identified a panel of five antigens
which when assayed together enable diagnosis of
tuberculosis infection with sensitivity and
selectivity at levels hitherto not obtained with
goats. The assaying for the presence of at least
two of the five antigens CFP-IO + Rv3616c + pepl
(MPB70) + MPB83 + MPB70 gave a sensitivity of 100%
and a specificity of 100% i.e. even higher than the
sensitivity and specificity obtained using the same
antigens in cattle.
Example 3 Identification of Panel of Antigens for
Diagnosis of TB in badgers
The inventors analysed antigen expression from 67
badgers, which had been confirmed TB positive by
histopathology and culture methods, using 133
badgers, which had been confirmed TB negative using
tuberculin skin tests, as the controls. The analysis
was carried out using the multiplex platform
described above in relation to Example 1 with the
following changes: 50µl of diluted sample and
diluted conjugate were added per well and 50µl of
prepared substrate was added per well instead of the
volumes recited in Example 1 ; moreover, the
conjugate used was affinity purified mAb CF2, anti-
badger IgG- HRP, which was used with appropriate
buffers and which was diluted to 1:100,000; the
samples were diluted to 1:450.
The inventors identified a panel of three antigens
which when assayed together, enable diagnosis of
tuberculosis infection with sensitivity and
specificity at levels hitherto not obtained with
badgers. The assaying for the presence of at least
one of the three antigens Rv3616c+ MPB83+ MPB70 gave
a sensitivity of 58.2%, compared to 52.2% obtained
with Rv3616c+ MPB70 alone, and 31.3% obtained using
MPB70 alone. The specificity obtained with Rv3616c+
MPB83+ MPB70 was 96.2%.
Example 4 Identification of Panel of Antigens for
Diagnosis of TB in wild boar and cervids
The inventors analysed antigen expression from 5
wild boar, which had been confirmed TB positive,
using 5 wild boar, which had been confirmed TB
negative, as the controls. The analysis was carried
out using the multiplex platform described above in
relation to Example 1 with the following changes:
50µl of diluted sample and diluted conjugate were
added per well and 40µl of prepared substrate was
added per well instead of the volumes recited in
Example 1 ; moreover, the sample incubation time was
90 minutes and the conjugate incubation time was 30
minutes; samples were diluted to 1:200; the
conjugate used was rabbit anti-pig IgG whole
molecule peroxidase conjugate with appropriate
buffers and was diluted to 1:40,000
The inventors identified a panel of four antigens
which when assayed together enable diagnosis of
tuberculosis infection with sensitivity and
selectivity at levels hitherto not obtained with
wild boar. The assaying for the presence of at
least two of the four antigens MPB70 + MPB83+
Rv3616c+CFP-10 gave a sensitivity of 100% and a
specificity of 100%.
The inventors also analysed antigen expression in a
further cohort of 45 wild boar confirmed positive
for TB infection with M.bovis, using 102 wild boar,
which had been confirmed TB negative, as the
controls. The assaying for the presence of at least
two of the four antigens MPB70 + MPB83+ Rv3616c+CFP-
10 again demonstrated high levels of sensitivity and
specificity using these antigens, the specificity
being 97.1% and the sensitivity being 72.7%.
The inventors also analysed antigen expression in a
further cohort of 10 wild boar confirmed positive
for TB infection with M .caprae, using 102 wild boar,
which had been confirmed TB negative, as the
controls. The assaying for the presence of at least
two of the four antigens MPB70 + MPB83+ Rv3616c+CFP-
10 again demonstrated high levels of sensitivity and
specificity using these antigens, the specificity
being 97.1% and the sensitivity being 60%.
The inventors also analysed antigen expression from
20 cervids, which had been confirmed TB positive,
using 20 cervids, which had been confirmed TB
negative, as the controls. The analysis was carried
out using the multiplex platform described above in
relation to Example 1 with the following changes:
50µl of diluted sample and diluted conjugate were
added per well and 40µl of prepared substrate was
added per well instead of the volumes recited in
Example 1 ; moreover, the sample incubation time was
90 minutes and the conjugate incubation time was 30
minutes; the conjugate used was affinity purified
antibody, peroxidase labelled, rabbit anti-deer IgG
H+L which was used with appropriate buffers and was
diluted to 1:100.
The panel of four antigens as employed with the
identification of TB infection in wild boar was
found when assayed together to enable diagnosis of
tuberculosis infection with high sensitivity and
selectivity with cervids . The assaying for the
presence of at least one of the four antigens MPB70
+ MPB83+ Rv3616c+CFP-10 gave a sensitivity of 70%
and a specificity of 100%.
All documents referred to in this specification are
herein incorporated by reference. Various
modifications and variations to the described
embodiments of the inventions will be apparent to
those skilled in the art without departing from the
scope and spirit of the invention. Although the
invention has been described in connection with
specific preferred embodiments, it should be
understood that the invention as claimed should not
be unduly limited to such specific embodiments.
Indeed, various modifications of the described modes
of carrying out the invention which are obvious to
those skilled in the art are intended to be covered
by the present invention.
Table 1
SEQ ID NO: 1 - Rv3616C (full length)
MSRAFIIDPT ISAIDGLYDL LGIGIPNQGG ILYSSLEYFE
KALEELAAAF PGDGWLGSAA DKYAGKNRNH VNFFQELADL
DRQLISLIHD QANAVQTTRD ILEGAKKGLE FVRPVAVDLT
YIPVVGHALS AAFQAPFCAG AMAVVGGALA YLVVKTLINA
TQLLKLLAKL AELVAAAIAD IISDVADI IK GTLGEVWEFI
TNALNGLKEL WDKLTGWVTG LFSRGWSNLE SFFAGVPGLT
GATSGLSQVT GLFGAAGLSA SSGLAHADSL ASSASLPALA
GIGGGSGFGG LPSLAQVHAA STRQALRPRA DGPVGAAAEQ
VGGQSQLVSA QGSQGMGGPV GMGGMHPSSG ASKGTTTKKY
SEGAAAGTED AERAPVEADA GGGQKVLVRN VV
SEQ ID NO: 2 - residues 300-370 of Rv3616c (Mtb40) :
ASTRQALRPRADGPVGAAAEQVGGQSQLVSAQGSQGMGGPVGMGGMHPSSGA
SKGTTTKKYSEGAAAGTED
SEQ ID NO: 3 - residues 35-94 of Rv3616c:
SLEYFEKALEELAAAFPGDGWLGSAADKYAGKNRNHVNFFQELADLDRQLIS
LIHDQANA
SEQ ID NO: 4 - residues 1-34 of Rv3616c:
MSRAFIIDPTISAIDGLYDLLGIGIPNQGGILYS
SEQ ID NO: 5 - residues 95-392 of Rv3616c:
VQTTRDILEGAKKGLEFVRPVAVDLTYIPVVGHALSAAFQAPFCAGAMAVVG
GALAYLVVKTLINATQLLKLLAKLAELVAAAIADIISDVADIIKGTLGEVWE
FITNALNGLKELWDKLTGWVTGLFSRGWSNLESFFAGVPGLTGATSGLSQVT
GLFGAAGLSASSGLAHADSLASSASLPALAGIGGGSGFGGLPSLAQVHAAST
RQALRPRADGPVGAAAEQVGGQSQLVSAQGSQGMGGPVGMGGMHPSSGASKG
TTTKKYSEGAAAGTEDAERAPVEADAGGGQKVLVRNVV
SEQ ID NO: 6 - MPB70
MKVKNTIAATSFAAAGLAALAVAVSPPAAAGDLVGPGCAEYAAANPTGPASV
QGMSQDPVAVAASNNPELTTLTAALSGQLNPQVNLVDTLNSGQYTVFAPTNA
AFSKLPASTIDELKTNSSLLTSILTYHVVAGQTSPANVVGTRQTLQGASVTV
TGQGNSLKVGNADVVCGGVSTANATVYMIDSVLMPPA
SEQ ID NO: 7 - PEP1(MPB7O):
KGSGS SVQGMSQDPVAVAASNNPEL
SEQ ID NO: 8 - MPB83
MINVQAKPAAAASLAAIAIAFLAGCSSTKPVSQDTSPKPATSPAAPVTTAAM
ADPAADLIGRGCAQYAAQNPTGPGSVAGMAQDPVATAASNNPMLSTLTSALS
GKLNPDVNLVDTLNGGEYTVFAPTNAAFDKLPAATIDQLKTDAKLLSSILTY
HVIAGQASPSRIDGTHQTLQGADLTVIGARDDLMVNNAGLVCGGVHTANATV
YMIDTVLMPPAQ
SEQ ID NO: 9 - Rv3875 (ESAT6) :
TEQQWNFAGIEAAASAIQGNVTSIHSLLDEGKQSLTKLAAAWGGSGSEAYQG
VQQKWDATATELNNALQNLARTISEAGQAMASTEGNVTGMFA
SEQ ID NO: 10 - Rv3874 (CFPlO) :
AEMKTDAATLAQEAGNFERISGDLKTQIDQVESTAGSLQGQWRGAAGTAAQA
AVVRFQEAANKQKQELDEISTNIRQAGVQYSRADEEQQQALSSQMGF
SEQ ID NO: 11 - PEP4 (CFPlO)
KGSGS MAEMKTDAATLAQEAGN
SEQ ID NO: 12 - PEP9 (CFPlO)
KGSGS NIRQAGVQYSRADEEQQQ
SEQ ID NO: 13 - PEP 17 (CFPlO)
VVRFQEAANKQKQELDE I
SEQ ID NO: 14 - Rvl573:
MTTTPARFNHLVTVTDLETGDRAVCDRDQVAETIRAWFPDAPLEVREALVRL
QAALNRHEHTGELEAFLRISVEHADAAGGDECGPAILAGRSGPEQAAINRQL
GLAGDDEPDGDDTPPWSRMIGLGGGSPAEDER
SEQ ID NO: 15 - Rvl580c:
MAETPDHAELRRRIADMAFNADVGMATCKRCGDAVPYI ILPNLQTGEPVMGV
ADNKWKRANCPVDVGKPCPFLIAEGVADSTDDTIEVDQ
SEQ ID NO: 16 - Rvl585c:
MSRHHNIVIVCDHGRKGDGRIEHERCDLVAPI IWVDETQGWLPQAPAVATLL
DDDNQPRAVIGLPPNESRLRPEMRRDGWVRLHWEFACLRYGAAGVRTCEQRP
VRVRNGDLQTLCENVPRLLTGLAGNPDYAPGFAVQS DAVVVAMWLWRTLCE S
DTPNKLRATPTRGSC
Claims
1 . An assay for the detection of the presence of
Mycobacterium, in a biological sample, said method
comprising the steps:
providing a biological sample from said animal;
and determining the presence or absence of a group
of antigens, or the presence or absence of an immune
response to each member of said group of antigens,
wherein said group of antigens comprises the group
consisting of (i)an Rv3616 antigen, (ii) an MPB70
antigen, (iii) an MPB70 linear epitope, for example
PEPl (MPB70) (iv) an MPB83 antigen, and (v) at least
one of (a) a CFPlO antigen and (b) an ESAT 6
antigen;
wherein the identification of the presence of
two or more of said antigens or of an immune
response thereto is indicative of the presence of
Mycobacterium in the biological sample.
2 . The method according to claim 1 wherein the
Mycobacterium is Mycobacterium bovis.
3 . The method according to claim 1 or claim 2 ,
wherein the identification of the presence of two or
more of said antigens of said group of antigens, or
of an immune response thereto, is indicative of the
presence of tuberculosis infection in the animal.
4 . The method according to any one of the
preceding claims, further comprising determining the
presence or absence of at least one of the antigens,
or an immune response to at least one of the
antigens, of the group consisting of an Rvl573
antigen, an Rvl580c antigen or an Rvl585c antigen.
5 . The method according to claim 4 , wherein the
identification of the presence of one or more of the
antigens, or an immune response to at least one of
the antigens, of the group consisting of an Rvl573
antigen, an Rvl580c antigen or an Rvl585c antigen is
indicative of the presence of, or infection with,
Mycobacterium bovis.
6 . The method according to any one of claims 1 to
3 , wherein the group of antigens consists of (i) an
Rv3616 antigen, (ii) an MPB70 antigen, (iii) an
MPB70 linear epitope, for example PEPl (MPB70) (iv)
an MPB83 antigen, and (v) at least one of (a) a
CFPlO antigen and (b) an ESAT 6 antigen.
7 . The method according to any one of claims 1 to
3 or 6 , wherein the group of antigens comprises (a)
a CFPlO antigen but does not comprise (b) an ESAT-6
antigen .
8. The method according to any one of claims 1 to
7 , wherein the animal is a bovid.
9 . The method according to claim 8 , wherein the
animal is a goat or a cow.
10. An assay method for the detection of the
presence of Mycobacterium, for example Mycobacterium
bovis, in a biological sample from an animal, for
example a reservoir mammal, the method comprising
the steps:
providing a biological sample from said animal; and
determining the presence or absence of a group of
antigens, or the presence or absence of an immune
response to each member of said group of antigens,
wherein said group of antigens comprises an Rv3616
antigen, an MPB70 antigen, and an MPB83 antigen,
wherein the identification of the presence of one or
more of said antigens of said group of antigens, or
of an immune response thereto, is indicative of the
presence of tuberculosis infection in the animal.
11. The method according to claim 10, wherein the
identification of the presence of one or more of
said antigens of said group of antigens, or of an
immune response thereto, is indicative of the
presence of tuberculosis infection in the animal.
12. The method according to claim 10 or claim 11,
wherein the method does not comprise determining the
presence or absence of any mycobacterial antigen, or
an immune response thereto, other than an Rv3616
antigen, an MPB70 antigen, and an MPB83 antigen.
13. The method according to any one of claims 10 to
12, wherein said mammal is a badger.
14. The method according to claim 10 or claim 11,
wherein said method further comprises determining
the presence or absence of an immune response to a
CFP-10 antigen.
15. The method according to claim 14, wherein the
method does not comprise determining the presence or
absence of any mycobacterial antigen, or an immune
response thereto, other than an Rv3616 antigen, an
MPB70 antigen, an MPB83 antigen, and a CFP-IO
antigen .
16. The method according to claim 15, wherein said
mammal is a suidae mammal, for example wild boar, or
a cervid.
17. The method according to any one of the
preceding claims wherein the presence of said one or
more antigens is determined by determining the
presence of an antibody response to said antigens.
18. The method according to any one of claims 1 to
16 wherein the presence of said one or more antigens
is determined by determining the presence of a
nucleic acid encoding said antigen or by determining
the presence of a nucleic acid encoding an antibody
to said antigen.
19. A diagnostic kit for the diagnosis of the
presence of tuberculosis in a subject, said kit
comprising :
(i)an Rv3616 antigen, (ii) an MPB70 antigen, (iii)
an MPB70 linear epitope, for example PEPl (MPB70)
(iv) an MPB83 antigen, and (v) at least one of (a) a
CFPlO antigen and (b) an ESAT 6 antigen.
20. The kit according to claim 19, wherein the kit
comprises each of the antigens of the group
consisting of (i) an Rv3616 antigen, (ii) an MPB70
antigen, (iii) an MPB70 linear epitope, for example
PEPl (MPB70) (iv) an MPB83 antigen, and (v) at least
one of (a) a CFPlO antigen and (b) an ESAT 6
antigen, but does not comprise another mycobacterial
antigen .
21. The kit according to claim 20, wherein the kit
comprises (a) a CFPlO antigen but does not comprise
(b) an ESAT-6 antigen.
22. A diagnostic kit for the diagnosis of the
presence of tuberculosis in a biological sample,
said kit comprising:
(i) an antibody molecule with binding specificity
for an Rv3616 antigen, (ii) an antibody molecule
with binding specificity for an MPB70 antigen, (iii)
an antibody molecule with binding specificity for an
MPB70 linear epitope, for example PEPl (MPB70) (iv)
an antibody molecule with binding specificity for an
MPB83 antigen, and (v) at least one of (a) an
antibody molecule with binding specificity for a
CFPlO antigen and (b) an antibody molecule with
binding specificity for an ESAT 6 antigen.
23. The diagnostic kit according to claim 22,
wherein the kit does not comprise an antibody
molecule with binding specificity for any
mycobacterial antigen other than for a Rv3616
antigen, an MPB70 antigen, an MPB70 linear epitope,
for example PEPl (MPB70), an MPB83 antigen, a CFPlO
antigen or an ESAT 6 antigen.
24. The kit according to claim 22 or claim 23,
wherein the kit comprises (a) an antibody molecule
with binding specificity for a CFPlO antigen, but
does not comprise (b) an antibody molecule with
binding specificity for an ESAT-6 antigen.
25. A diagnostic kit for the diagnosis of the
presence of tuberculosis in a biological sample from
a reservoir animal, said kit comprising an Rv3616
antigen, an MPB70 antigen, and a MPB83 antigen.
26. A diagnostic kit for the diagnosis of the
presence of tuberculosis in a biological sample from
a reservoir animal, said kit comprising: an antibody
molecule with binding specificity for an Rv3616
antigen, an antibody molecule with binding
specificity for an MPB70 antigen, and an antibody
molecule with binding specificity for an MPB83
antigen .
27. The diagnostic kit according to claim 25
wherein the kit does not comprise a mycobacterial
antigen other than an Rv3616 antigen, an MPB70
antigen, and a MPB83 antigen.
28. The diagnostic kit according to claim 26
wherein the kit does not comprise an antibody
molecule with binding specificity for a
mycobacterial antigen other than for an Rv3616
antigen, an MPB70 antigen, or a MPB83 antigen.
29. The diagnostic kit according to any one of
claims 25 to 28, wherein said animal is a badger.
30. The diagnostic kit according to claim 25
further comprising a CFPlO antigen.
31. The diagnostic kit according to claim 26
further comprising an antibody molecule with binding
specificity for a CFPlO antigen.
32. The diagnostic kit according to claim 30
wherein the kit does not comprise a mycobacterial
antigen other than an Rv3616 antigen, an MPB70
antigen, a MPB83 antigen, and a CFPlO antigen.
33. The diagnostic kit according to claim 31
wherein the kit does not comprise an antibody
molecule with binding specificity for a
mycobacterial antigen other than an Rv3616 antigen,
an MPB70 antigen, a MPB83 antigen, and a CFPlO
antigen .
34. The kit according to any one of claims 30 to
33, wherein said animal is a suidae mammal, for
example wild boar, or a cervid.
35. A vaccine comprising an Rv3616 antigen, an
MPB70 antigen, and an MPB83 antigen.
36. The vaccine according to claim 35 wherein the
vaccine does not comprise another mycobacterial
antigen .
37. The vaccine according to claim 35 further
comprising a CFPlO antigen.
38. The vaccine according to claim 37 wherein the
vaccine does not comprise another mycobacterial
antigen.
39. A vaccine comprising (i)an Rv3616 antigen, (ii)
an MPB70 antigen, (iii) an MPB70 linear epitope, for
example PEPl (MPB70) (iv) an MPB83 antigen, and (v)
at least one of (a) a CFPlO antigen and (b) an ESAT
6 antigen.
40. The vaccine according to claim 39, wherein the
vaccine does not comprise an ESAT 6 antigen.
41. The vaccine according to claim 40, wherein the
vaccine does not comprise another mycobacterial
antigen .
42. The method according to claim 16, wherein the
mammal is a suidae mammal, for example wild boar,
and the identification of the presence of two of
said antigens of said group of antigens, or of an
immune response thereto, is indicative of the
presence of tuberculosis infection in the suidae
mammal .
43. The method according to claim 16, wherein the
mammal is a cervid and the identification of the
presence of one of said antigens of said group of
antigens, or of an immune response thereto, is
indicative of the presence of tuberculosis infection
in the cervid.
44. The method according to claim 9 , wherein the
mammal is a goat and the identification of the
presence of two of said antigens of said group of
antigens, or of an immune response thereto, is
indicative of the presence of tuberculosis infection
in the goat.
Internat ona app cation No
INTERNATIONAL SEARCH REPORT
PCT/GB2010/050324
A CLASSIFICATION OF SUBJECT MATTER ,
INV. A61K39/04 G01N33/569
According to International Patent Classification (IPC) or to both national classification and IPC
B FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
A61K GOlN
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal , BIOSIS, EMBASE, WPI Data
C. DOCUMENTS CONSIDERED TO BE RELEVANT
Category * Citation of document with indication, where appropriate, of the relevant passages Relevant to claim No
X ,P WO 2009/024822 A2 (FUSION ANTIBODIES LTD 1-9,
[GB]; ENFER TECHNOLOGY LTD [IE]; OLWILL 17-24,
SHANE A ) 26 February 2009 (2009-02-26) 39-41,44
the whole document
WO 2006/117538 A2 (FUSION ANTIBODIES LTD 1-9,
[GB]; OLWILL SHANE A [GB]; BUICK RICHARD J 17-24,
[GB];) 9 November 2006 (2006-11-09) 39-41,44
claim 1
pages 7-10
claim 13
-/--
Further documents are listed in the continuation of Box C See patent family annex
* Special catego pies of cited documents
"T" later document published after the international filing date
or ppiopity date and not in conflict with the application but
"A" document defining the general state of the art which is not cited to understand the principle or theory underlying the
considered to be of particular relevance invention
Ε " earlier document but published on or after the international
"X" document of particular relevance, the claimed inventionfiling date cannot be considered novel or cannot be considered to
"L' document which may throw doubts on ppionty cla ιm(s) or involve an inventive step when the document is taken alone
which is cited to establish the publication date of another
"Y" document of particular relevance the claimed invention
citation or other special reason (as specified) cannot be considered to involve an inventive step when the
O " document referping to an oral disclosure, use, exhibition or document is combined with one or more other such docu
other means ments, such combination being obvious to a person skilled
"P" document published prior to the international filing date but in the art
later than the priority date claimed "&" document member of the same patent family
Date of the actual completion of the international search Date of mailing of the international search report
7 May 2010 30/07/2010
Name and mailing address of the ISA/ Authorized officer
European Patent Office, P B 5818 Patepitlaan 2
NL - 2280 HV RijSWljk
TeI (+31-70) 340-2040,
Fax (+31-70) 340-3016 Hohwy, Morten
Form PCT/ISA/210 (second sheel) (April 2005)
n on o
INTERNATIONAL SEARCH REPORT PCT/GB2010/050324
C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT
Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No
Y LIU ET AL: "A novel fusi on protein-based 1-9 ,
i ndi rect enzyme-l inked immunosorbent assay 17-24,
for the detection of bovine tubercul osi s " 39-41 ,44
TUBERCULOSIS, ELSEVIER, GB LNKD-
DOI : 10 . 1016/ J . TUBE . 2006 . 07 . 007 ,
vol . 87, no. 3 ,
11 Apri l 2007 (2007-04-11 ) , pages 212-217,
XP022020620
ISSN: 1472-9792
abstract
Y LYASHCHENKO K P ET AL: "PrimaTB STAT-PAK 1-9 ,
assay, a novel , rapid lateral-fl ow test 17-24,
for tubercul osi s i n nonhuman primates" 39-41 ,44
CLINICAL AND VACCINE IMMUNOLOGY, AMERICAN
SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC ,
US LNKD- DOI : 10 . 1128/CVI . 00230-07 ,
vol . 14, no. 9 ,
1 September 2007 (2007-09-01 ) , pages
1158-1164, XP002511617
ISSN: 1556-6811 [retrieved on 2007-07-25]
page 1161
page 1160, column 1 ; table 2
table 4
Y WATERS W R ET AL: "Antibody responses i n 1-9,
reindeer (Rangifer tarandus) infected with 17-24,
Mycobacterium bovi s " 39-41 ,44
CLINICAL AND DIAGNOSTIC LABORATORY
IMMUNOLOGY, AMERICAN SOCIETY FOR
MICROBIOLOGY, US LNKD-
DOI : 10 . 1128/CDLI . 12 . 6 . 727-735 . 2005,
vol . 12, no. 6 , 1 June 2005 (2005-06-01 ) ,
pages 727-735, XP002511618
ISSN : 1071-412X
page 728, col umn 2 ; table 2
Y WIKER H G ET AL: "Immunochemical 1-9,
characterization of the MPB70/80 and MPB83 17-24,
proteins of Mycobacterium bovi s . " 39-41 ,44
INFECTION AND IMMUNITY APR 1998 LNKD-
PUBMED: 9529066,
vol . 66, no. 4 , Apri l 1998 (1998-04) ,
pages 1445-1452, XP002579405
ISSN : 0019-9567
figures 5,6,8
Form PCT/IS Λ/21O (continuation of second sheet) (April 2005)
International application No
INTERNATIONAL SEARCH REPORT PCT/GB2010/050324
Box No. Il Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This international search report has not been established in respect oi certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. I M Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. I As all required additional search fees were timely paid by the applicant, this international search report covers all searchable
claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of
additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers
only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
2 1 , 24, 40, 41(completely); 1-9, 17-20, 22, 23, 39, 44(partial ly)
Remark on Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the
payment of a protest fee.
The additional search fees were accompanied by the applicant's protest but the applicable protest
fee was not paid within the time limit specified in the invitation.
No protest accompanied the payment of additional search fees.
Form PCT/ISA/21 0 (continuation of first sheet (2)) (April 2005)
International Application No. PCT/GB20 10 /050324
FURTHER INFORMATION CONTINUED FROM POT/ISA/ 2 10
This International Searching Authority found multiple (groups of)
inventions in this international application, as follows:
1 . claims: 21, 24, 40, 41(completely); 1-9, 17-20, 22, 23, 39,
44(partially)
A method for detecting mycobacteria comprising detecting
antigens or an immune response to said antigens, a
diagnostic kit comprising said antigens, a diagnostic kit
comprising antibodies to said antigens, and a vaccine
comprising said antigens, wherein the antigens are: an
Rv3616 antigen, an MPB70 antigen, an MPB70 linear antigen
(such as PEPl), an MPB83 antigen, and a CFPlO antigen.
2 . claims: 1-9, 17-20, 22, 23, 39, 44(all partially)
A method for detecting mycobacteria comprising detecting
antigens or an immune response to said antigens, a
diagnostic kit comprising said antigens, a diagnostic kit
comprising antibodies to said antigens, and a vaccine
comprising said antigens, wherein the antigens are: an
Rv3616 antigen, an MPB70 antigen, an MPB70 linear antigen
(such as PEPl), an MPB83 antigen, and an ESAT6 antigen.
3 . claims: 10-16, 25-29, 35, 36, 42, 43(completely); 17,
18(partially)
A method for detecting mycobacteria comprising detecting
antigens or an immune response to said antigens, a
diagnostic kit comprising said antigens, a diagnostic kit
comprising antibodies to said antigens, and a vaccine
comprising said antigens, wherein the antigens are: an
Rv3616 antigen, an MPB70 antigen, and an MPB83 antigen.
4 . claims: 30-34, 37, 38
A diagnostic kit comprising antigens, a diagnostic kit
comprising antibodies to said antigens, and a vaccine
comprising said antigens, wherein the antigens are: an
Rv3616 antigen, an MPB70 antigen, an MPB83 antigen, and a
CFPlO antigen.
Interna ona app cation No
Information on patent family members
PCT/GB2010/050324
Patent document Publication Patent family Publication
cited in search report date member(s) date
WO 2009024822 A2 26-02-2009 NONE
WO 2006117538 A2 09-11-2006 CA 2606962 Al 09-11-2006
EP 1904848 A2 02-04-2008
US 2009053258 Al 26-02-2009
Form PCT/ISA/210 (patent family annex) (April 2005)
